在大肠杆菌中抗抑郁药psilocybin的de novo生物合成
Zhangrao Huang1,2, Yongpeng Yao1, Rouyu Di1,2
1State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People's Republic of China.
Microbial biotechnology
|April 3, 2025
概括
研究人员对大肠杆菌进行了基因工程设计,以实现可持续的西生产. 经过修改的酶和优化的途径显著增加了西的产量,为负担得起的抗抑郁药制造铺平了道路.
科学领域:
- 生物技术是生物技术.
- 代谢工程是代谢工程.
- 微生物生产 微生物生产
背景情况:
- 三胺类类化合物psilocybin在治疗耐药抑郁症方面表现有前途,需要高效的生产方法.
- 目前的psilocybin制造受到表达像PsiH这样的真核酶在 prokaryotic 系统中的挑战所限制.
- 在大肠杆菌中进行新生合成是可持续和经济地生产psilocybin的一个有希望的途径.
研究的目的:
- 通过对关键酶PsiH进行工程来克服大肠杆菌中psilocybin生物合成的局限性.
- 建立一个强大的微生物平台,用于新生产西.
- 通过路径优化和发酵改进,显著提高psilocybin的产量.
主要方法:
- 具有修饰的N端域的真核细胞细胞染色体P450酶PsiH的工程变体.
- 在低温下表达了大肠杆菌中完整的西洛生物合成途径.
- 优化了前体供应,P450电子转移链,并过度表达了甲基转移酶基因psiM.
- 为了最大限度地生产psilocybin,优化了小瓶发酵条件.
主要成果:
- 在初始途径工程后,获得了33倍的诺贝奥西斯位数 (105.3 mg/L) 和17倍的 пси洛西宾位数 (14 mg/L) 的增加.
- 通过过度表达psiM,进一步增强了psilocybin的产生,将norbaeocystin转化为psilocybin.
- 达到79.4毫克/升的最终psilocybin标位,比基线菌株改善100倍.
- 证明了真菌P450酶的成功工程,以改善大肠杆菌的催化活性.
结论:
- 工程设计的PsiH变体和优化的途径使大肠杆菌中高效的新型psilocybin合成成为可能.
- 这项研究在微生物生产西方面取得了重大进展,西是治疗抑郁症的关键化合物.
- 开发的微生物平台支持可持续和经济高效地制造用于治疗应用的psilocybin.
更多相关视频
11:51Engineering 'Golden' Fluorescence by Selective Pressure Incorporation of Non-canonical Amino Acids and Protein Analysis by Mass Spectrometry and Fluorescence
Published on: April 27, 2018
11.9K
11:13Mass Spectrometry-Guided Genome Mining as a Tool to Uncover Novel Natural Products
Published on: March 12, 2020
10.8K
相关概念视频
Biosynthesis in Bacteria
Biosynthesis in bacteria is a fundamental anabolic process that generates essential macromolecules, including proteins, nucleic acids, lipids, and polysaccharides. These macromolecules are critical for cellular growth, replication, and function. The process is tightly regulated and energetically linked to catabolic pathways to ensure optimal resource utilization.Biosynthetic pathways begin with precursor metabolites such as pyruvate, acetyl-CoA, and glucose-6-phosphate derived from glycolysis,...
Stringent Response in E. coli
Bacterial growth is closely tied to nutrient availability, with cells proliferating exponentially under favorable conditions and entering a stationary phase when resources become scarce. This transition is mediated by a regulatory mechanism known as the stringent response, which allows bacteria to adapt to nutrient deprivation by modulating gene expression and metabolic activity.During nutrient scarcity, intracellular amino acid levels decline. It results in the accumulation of uncharged tRNAs...
Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
